AlzeCure receives EU grant for Phase 2 clinical trial of NeuroRestore ACD856 for Alzheimer’s disease
February 17, 2025
“The grant we received from the European Innovation Council is a strong validation of NeuroRestore ACD856, which has a unique pharmacological mechanism that en...
AlzeCure´s CEO, Martin Jönsson and CSO, Johan Sandin attend JP Morgan in San Francisco, January 13 – 16, 2025
February 4, 2025
Read more: https://www.biocentury.com/jpm-guide
AlzeCure presents new anti-inflammatory data with NeuroRestore ACD856 at the Alzheimer’s conference CTAD
October 17, 2024
AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer&#...